Dotamtate is a somatostatin‑receptor–targeting peptide ligand that serves as the drug substance (ligand component) for the radiopharmaceutical 212Pb‑DOTAMTATE (AlphaMedix), an investigational targeted alpha‑emitter therapy for SSTR‑positive neuroendocrine tumors. As a standalone drug substance, Dotamtate is essentially a modified octreotate peptide bearing a macrocyclic chelator (DOTAM) for stable complexation with lead‑212 or other metals. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include UNII-J2KEK56NRS. It is also listed for alternate use as: API Intermediate. Its PubChem CID is 135228365.
Dotamtate
| CAS No | 2415661-92-4 |
|---|---|
| Molecular Formula | C65H93N17O16S2 |
| Molecular Weight | 1432.7 g/mol |
| Synonyms | (2S,3R)-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-3-phenyl-2-[[2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-hydroxybutanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dotamtate is a somatostatin‑receptor–targeting peptide ligand that serves as the drug substance (ligand component) for the radiopharmaceutical 212Pb‑DOTAMTATE (AlphaMedix), an investigational targeted alpha‑emitter therapy for SSTR‑positive neuroendocrine tumors.
The listed CAS number is 2415661-92-4.
The listed molecular formula is C65H93N17O16S2.
The listed molecular weight is 1432.7 g/mol.
(2S,3R)-2-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[(2R)-3-phenyl-2-[[2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-hydroxybutanoic acid.
The source lists UNII-J2KEK56NRS.